INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,280,424 | -16.0% | 24,581 | +2.1% | 0.01% | -8.3% |
| Q2 2023 | $1,525,126 | +14.0% | 24,086 | -2.5% | 0.01% | 0.0% |
| Q1 2023 | $1,337,343 | +5.4% | 24,697 | +3.0% | 0.01% | 0.0% |
| Q4 2022 | $1,268,704 | +18.2% | 23,974 | +3.9% | 0.01% | +9.1% |
| Q3 2022 | $1,073,000 | -16.5% | 23,069 | +2.4% | 0.01% | -8.3% |
| Q2 2022 | $1,285,000 | -5.2% | 22,519 | +1.7% | 0.01% | +9.1% |
| Q1 2022 | $1,355,000 | +39.1% | 22,136 | +19.0% | 0.01% | +57.1% |
| Q4 2021 | $974,000 | +38.9% | 18,609 | -1.0% | 0.01% | +16.7% |
| Q3 2021 | $701,000 | -8.1% | 18,801 | +0.6% | 0.01% | 0.0% |
| Q2 2021 | $763,000 | +7.0% | 18,696 | -11.0% | 0.01% | 0.0% |
| Q1 2021 | $713,000 | +8.9% | 21,001 | +1.9% | 0.01% | 0.0% |
| Q4 2020 | $655,000 | +41.5% | 20,612 | +14.2% | 0.01% | +20.0% |
| Q3 2020 | $463,000 | +33.0% | 18,045 | +33.2% | 0.01% | 0.0% |
| Q2 2020 | $348,000 | +64.2% | 13,549 | -1.7% | 0.01% | +25.0% |
| Q1 2020 | $212,000 | – | 13,789 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |